| Public Notice | Monitoring | N/A | N/A | Jan 8, 2025 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.023 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | May 6, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 6, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.024 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.024 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.024 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.024 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.024 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |